Search research articles
Contact Us
Filters
Showing results (41-50 of 80) with videos related to
Page
of 8
Sort By:
Fitoterapia
|
March 14, 2026
From computational prediction to in vitro experimental validation: Identifying active compounds in longan leaves and their anti-colorectal cancer mechanisms
Jinrui Wei, Yuxin Xie, Jianfeng Qin, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
May 23, 2012
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer]
Jianjie Li, Lili Qu, Xing Wei, et al.
Frontiers in Physiology
|
January 10, 2022
Hyperreflective Foci and Subretinal Fluid Are Potential Imaging Biomarkers to Evaluate Anti-VEGF Effect in Diabetic Macular Edema
Shiyue Qin, Chaoyang Zhang, Haifeng Qin, et al.
World Journal of Surgical Oncology
|
September 26, 2023
Application of MFI-5 in severe complications and unfavorable outcomes after radical resection of colorectal cancer
Lihong Huang, Zhifa Li, Mengru Jian, et al.
Journal of Clinical Pathology
|
July 27, 2013
The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies
Xiaoqing Liu, Yachao Lu, Guanshan Zhu, et al.
Molecular Medicine Reports
|
November 21, 2019
Exploratory study on application of MALDI‑TOF‑MS to detect serum and urine peptides related to small cell lung carcinoma
Panpan Lv, Zeyuan Liu, Bin Xu, et al.
Oncology Letters
|
March 31, 2017
CD147 promotes the proliferation, invasiveness, migration and angiogenesis of human lung carcinoma cells
Shaoxing Yang, Fei Qi, Chuanhao Tang, et al.
Annals of Translational Medicine
|
March 26, 2019
Aprepitant for gefitinib-induced refractory pruritus in Chinese malignancy population
Haifeng Qin, Fang Wang, Ke Wang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
July 23, 2013
[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?]
Chuanhao Tang, Xiaoyan Li, Wanfeng Guo, et al.
Frontiers of Medicine
|
July 17, 2022
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
Jianhua Shi, Ying Cheng, Qiming Wang, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 80) with videos related to
Sort By:
Page
of 8
Fitoterapia
|
March 14, 2026
From computational prediction to in vitro experimental validation: Identifying active compounds in longan leaves and their anti-colorectal cancer mechanisms
Jinrui Wei, Yuxin Xie, Jianfeng Qin, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
May 23, 2012
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer]
Jianjie Li, Lili Qu, Xing Wei, et al.
Frontiers in Physiology
|
January 10, 2022
Hyperreflective Foci and Subretinal Fluid Are Potential Imaging Biomarkers to Evaluate Anti-VEGF Effect in Diabetic Macular Edema
Shiyue Qin, Chaoyang Zhang, Haifeng Qin, et al.
World Journal of Surgical Oncology
|
September 26, 2023
Application of MFI-5 in severe complications and unfavorable outcomes after radical resection of colorectal cancer
Lihong Huang, Zhifa Li, Mengru Jian, et al.
Journal of Clinical Pathology
|
July 27, 2013
The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies
Xiaoqing Liu, Yachao Lu, Guanshan Zhu, et al.
Molecular Medicine Reports
|
November 21, 2019
Exploratory study on application of MALDI‑TOF‑MS to detect serum and urine peptides related to small cell lung carcinoma
Panpan Lv, Zeyuan Liu, Bin Xu, et al.
Oncology Letters
|
March 31, 2017
CD147 promotes the proliferation, invasiveness, migration and angiogenesis of human lung carcinoma cells
Shaoxing Yang, Fei Qi, Chuanhao Tang, et al.
Annals of Translational Medicine
|
March 26, 2019
Aprepitant for gefitinib-induced refractory pruritus in Chinese malignancy population
Haifeng Qin, Fang Wang, Ke Wang, et al.
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|
July 23, 2013
[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?]
Chuanhao Tang, Xiaoyan Li, Wanfeng Guo, et al.
Frontiers of Medicine
|
July 17, 2022
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
Jianhua Shi, Ying Cheng, Qiming Wang, et al.
Page
of 8